Recommendation for vaccinations in patients with Crohn's disease and ulcerative colitis on immunosuppressive and/or biological therapy;Doporučení pro vakcinaci nemocných s Crohnovou chorobou a ulcerózní kolitidou na imunosupresivní a biologické léčbě

Ceska a Slovenska Gastroenterologie a Hepatologie

Volumn 64, Issue 1, 2010, Pages 40-48

  Stehlik J ^a   Mares K ^b   Lukáš, Milan ^c   Bortlik M ^c   Duricova D ^c  

^a Department of Anesthesiology   (Czech Republic)

^b NA HOMOLCE HOSPITAL   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biological therapy; Crohn's disease; Immunosuppressive therapy; Inflammatory bowel diseases; Ulcerative colitis; Vaccinations

Indexed keywords

BIOLOGICAL THERAPY; CHOLERA; CROHN DISEASE; ENTERITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VIRUS A H1N1; MALARIA; NONHUMAN; OPPORTUNISTIC INFECTION; REVIEW; ULCERATIVE COLITIS; VACCINATION; VARICELLA ZOSTER VIRUS; WART VIRUS;

EID: 77749323193     PISSN: 1213323X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Rutgeerts P, Vermeire S, Van AG. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136(5): 1182-1197.
2. de Ridder L, Escher JC, Bouquet J et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39(1): 46-52.
3. Caspersen S, Elkjaer M, Riis L et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6(11): 1212-1217.
4. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541-1549.
5. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56(9): 1232-1239.
6. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-508.
7. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58(4): 492-500.
8. Rahier J, Ben-Horin S, Chowers Y et al. Europen evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis 2009; 3: 47-91.
9. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098-1104.
10. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4(5): 621-630.
11. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 1993; 42:1-18.
12. Symmers WS. Opportunistic infections. The concept of "opportunistic infections". Proc R Soc Med 1965; 58: 341-346.
13. Toruner M, Loftus EV jr., Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134(4): 929-936.
14. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31(2): 578-585.
15. Ainley C, Cason J, Slavin BM et al. The influence of zinc status and malnutrition on immunological function in Crohn's disease. Gastroenterology 1991; 100(6): 1616-1625.
16. Lu Y, Jacobson DL, Ashworth LA et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009; 104(2): 444-453.
17. Brezinschek HP, HofstaetterT, Leeb BF et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol 2008; 20(3): 295-299.
18. Mamula P, Markowitz JE, Piccoli DA et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5(7): 851-856.
19. Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360(25): 2605-2615.
20. Baker MG, Wilson N, Huang QS et al. Pandemic influenza A(H1N1)V in New Zealand: the experience from April to August 2009. Euro Surveill 2009; 14.
21. Vaillant L, La RG, Tarantola A et al. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009; 14.
22. Rahier JF, Yazdanpanah Y, Viget N et al. Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31(1): 5-10.
23. Medicines Q&A: Use of Oseltamivir in Patients Taking Methotrexate. 2009.
24. Beasley RP, Hwang LY, Lin CC et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982; 146(2): 198-204.
25. Coursaget P, Yvonnet B, Chotard J et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987; 22(1): 1-5.
26. Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31(2): 488-495.
27. Rehermann B, Ferrari C, Pasquinelli C et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2(10): 1104-1108.
28. Yotsuyanagi H, Yasuda K, lino S et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998; 27(5): 1377-1382.
29. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45(2): 507-539.
30. Cheng AL, Hsiung CA, Su IJ et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37(6): 1320-1328.
31. Šperl J, Špičák J. Problematika virových hepatitid v průběhu léčby preparáty s antiTNFa aktivitou. Biol Lecbva 2010; 2:69.
32. Tilg H, Vogelsang H, Ludwiczek O et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003; 52(12): 1728-1733.
33. Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007; 15(4): 130-133.
34. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007; 38(3): 189-197.
35. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24.
36. Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57(1): 7-28.
37. Saunders W. The Imunology of Pregnancy. Maternal-fetal Medicine: Principles and Practice. Philadelphia, PA: 1994.
38. Mahadevan U, Terdiman J, Church J et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2010; 132: A144.
39. Vasiliauskas EA, Church JA, Silverman N et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4(10): 1255-1258.
40. Hill DR, Ericsson C, Pearson R et al. The practice of travel medicine: guidelines by the Infectious Disease Society of America. Clin Infect Dis 2006; 43: 1499-1539.